Abstract
Summary
TNF Alpha Inhibitor are a group of medicines that suppress the body's natural response to tumor necrosis factor (TNF), a protein produced by white blood cells that is involved in early inflammatory events.
The global market for TNF Alpha Inhibitor was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for TNF Alpha Inhibitor was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for TNF Alpha Inhibitor was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for TNF Alpha Inhibitor was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of TNF Alpha Inhibitor include AbbVie Inc., Amgen Inc., Johnson and Johnson, UCB SA, Novartis International AG, Pfizer, Merck and co., Janssen Biotech and Ablynx, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for TNF Alpha Inhibitor, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of TNF Alpha Inhibitor by region & country, by Type, and by Application.
The TNF Alpha Inhibitor market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding TNF Alpha Inhibitor.
Market Segmentation
By Company
AbbVie Inc.
Amgen Inc.
Johnson and Johnson
UCB SA
Novartis International AG
Pfizer
Merck and co.
Janssen Biotech
Ablynx
Momenta
Segment by Type:
Remicade (Infliximab)
Enbrel (Etanercept)
Humira (Adalimumab)
Cimzia (Certolizumab Pegol)
Simponi (Golimumab)
Segment by Application
Inflammatory Bowel Disease
Psoriatic Arthritis
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of TNF Alpha Inhibitor manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of TNF Alpha Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of TNF Alpha Inhibitor in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for TNF Alpha Inhibitor was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for TNF Alpha Inhibitor was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for TNF Alpha Inhibitor was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for TNF Alpha Inhibitor was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of TNF Alpha Inhibitor include AbbVie Inc., Amgen Inc., Johnson and Johnson, UCB SA, Novartis International AG, Pfizer, Merck and co., Janssen Biotech and Ablynx, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for TNF Alpha Inhibitor, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of TNF Alpha Inhibitor by region & country, by Type, and by Application.
The TNF Alpha Inhibitor market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding TNF Alpha Inhibitor.
Market Segmentation
By Company
AbbVie Inc.
Amgen Inc.
Johnson and Johnson
UCB SA
Novartis International AG
Pfizer
Merck and co.
Janssen Biotech
Ablynx
Momenta
Segment by Type:
Remicade (Infliximab)
Enbrel (Etanercept)
Humira (Adalimumab)
Cimzia (Certolizumab Pegol)
Simponi (Golimumab)
Segment by Application
Inflammatory Bowel Disease
Psoriatic Arthritis
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of TNF Alpha Inhibitor manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of TNF Alpha Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of TNF Alpha Inhibitor in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 TNF Alpha Inhibitor Product Introduction
1.2 Global TNF Alpha Inhibitor Market Size Forecast
1.3 TNF Alpha Inhibitor Market Trends & Drivers
1.3.1 TNF Alpha Inhibitor Industry Trends
1.3.2 TNF Alpha Inhibitor Market Drivers & Opportunity
1.3.3 TNF Alpha Inhibitor Market Challenges
1.3.4 TNF Alpha Inhibitor Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global TNF Alpha Inhibitor Players Revenue Ranking (2023)
2.2 Global TNF Alpha Inhibitor Revenue by Company (2019-2024)
2.3 Key Companies TNF Alpha Inhibitor Manufacturing Base Distribution and Headquarters
2.4 Key Companies TNF Alpha Inhibitor Product Offered
2.5 Key Companies Time to Begin Mass Production of TNF Alpha Inhibitor
2.6 TNF Alpha Inhibitor Market Competitive Analysis
2.6.1 TNF Alpha Inhibitor Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by TNF Alpha Inhibitor Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in TNF Alpha Inhibitor as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Remicade (Infliximab)
3.1.2 Enbrel (Etanercept)
3.1.3 Humira (Adalimumab)
3.1.4 Cimzia (Certolizumab Pegol)
3.1.5 Simponi (Golimumab)
3.2 Global TNF Alpha Inhibitor Sales Value by Type
3.2.1 Global TNF Alpha Inhibitor Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global TNF Alpha Inhibitor Sales Value, by Type (2019-2030)
3.2.3 Global TNF Alpha Inhibitor Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Inflammatory Bowel Disease
4.1.2 Psoriatic Arthritis
4.1.3 Ulcerative Colitis
4.1.4 Rheumatoid Arthritis
4.1.5 Ankylosing Spondylitis
4.1.6 Others
4.2 Global TNF Alpha Inhibitor Sales Value by Application
4.2.1 Global TNF Alpha Inhibitor Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global TNF Alpha Inhibitor Sales Value, by Application (2019-2030)
4.2.3 Global TNF Alpha Inhibitor Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global TNF Alpha Inhibitor Sales Value by Region
5.1.1 Global TNF Alpha Inhibitor Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global TNF Alpha Inhibitor Sales Value by Region (2019-2024)
5.1.3 Global TNF Alpha Inhibitor Sales Value by Region (2025-2030)
5.1.4 Global TNF Alpha Inhibitor Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America TNF Alpha Inhibitor Sales Value, 2019-2030
5.2.2 North America TNF Alpha Inhibitor Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe TNF Alpha Inhibitor Sales Value, 2019-2030
5.3.2 Europe TNF Alpha Inhibitor Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific TNF Alpha Inhibitor Sales Value, 2019-2030
5.4.2 Asia Pacific TNF Alpha Inhibitor Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America TNF Alpha Inhibitor Sales Value, 2019-2030
5.5.2 South America TNF Alpha Inhibitor Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa TNF Alpha Inhibitor Sales Value, 2019-2030
5.6.2 Middle East & Africa TNF Alpha Inhibitor Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions TNF Alpha Inhibitor Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions TNF Alpha Inhibitor Sales Value
6.3 United States
6.3.1 United States TNF Alpha Inhibitor Sales Value, 2019-2030
6.3.2 United States TNF Alpha Inhibitor Sales Value by Type (%), 2023 VS 2030
6.3.3 United States TNF Alpha Inhibitor Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe TNF Alpha Inhibitor Sales Value, 2019-2030
6.4.2 Europe TNF Alpha Inhibitor Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe TNF Alpha Inhibitor Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China TNF Alpha Inhibitor Sales Value, 2019-2030
6.5.2 China TNF Alpha Inhibitor Sales Value by Type (%), 2023 VS 2030
6.5.3 China TNF Alpha Inhibitor Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan TNF Alpha Inhibitor Sales Value, 2019-2030
6.6.2 Japan TNF Alpha Inhibitor Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan TNF Alpha Inhibitor Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea TNF Alpha Inhibitor Sales Value, 2019-2030
6.7.2 South Korea TNF Alpha Inhibitor Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea TNF Alpha Inhibitor Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia TNF Alpha Inhibitor Sales Value, 2019-2030
6.8.2 Southeast Asia TNF Alpha Inhibitor Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia TNF Alpha Inhibitor Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India TNF Alpha Inhibitor Sales Value, 2019-2030
6.9.2 India TNF Alpha Inhibitor Sales Value by Type (%), 2023 VS 2030
6.9.3 India TNF Alpha Inhibitor Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AbbVie Inc.
7.1.1 AbbVie Inc. Profile
7.1.2 AbbVie Inc. Main Business
7.1.3 AbbVie Inc. TNF Alpha Inhibitor Products, Services and Solutions
7.1.4 AbbVie Inc. TNF Alpha Inhibitor Revenue (US$ Million) & (2019-2024)
7.1.5 AbbVie Inc. Recent Developments
7.2 Amgen Inc.
7.2.1 Amgen Inc. Profile
7.2.2 Amgen Inc. Main Business
7.2.3 Amgen Inc. TNF Alpha Inhibitor Products, Services and Solutions
7.2.4 Amgen Inc. TNF Alpha Inhibitor Revenue (US$ Million) & (2019-2024)
7.2.5 Amgen Inc. Recent Developments
7.3 Johnson and Johnson
7.3.1 Johnson and Johnson Profile
7.3.2 Johnson and Johnson Main Business
7.3.3 Johnson and Johnson TNF Alpha Inhibitor Products, Services and Solutions
7.3.4 Johnson and Johnson TNF Alpha Inhibitor Revenue (US$ Million) & (2019-2024)
7.3.5 UCB SA Recent Developments
7.4 UCB SA
7.4.1 UCB SA Profile
7.4.2 UCB SA Main Business
7.4.3 UCB SA TNF Alpha Inhibitor Products, Services and Solutions
7.4.4 UCB SA TNF Alpha Inhibitor Revenue (US$ Million) & (2019-2024)
7.4.5 UCB SA Recent Developments
7.5 Novartis International AG
7.5.1 Novartis International AG Profile
7.5.2 Novartis International AG Main Business
7.5.3 Novartis International AG TNF Alpha Inhibitor Products, Services and Solutions
7.5.4 Novartis International AG TNF Alpha Inhibitor Revenue (US$ Million) & (2019-2024)
7.5.5 Novartis International AG Recent Developments
7.6 Pfizer
7.6.1 Pfizer Profile
7.6.2 Pfizer Main Business
7.6.3 Pfizer TNF Alpha Inhibitor Products, Services and Solutions
7.6.4 Pfizer TNF Alpha Inhibitor Revenue (US$ Million) & (2019-2024)
7.6.5 Pfizer Recent Developments
7.7 Merck and co.
7.7.1 Merck and co. Profile
7.7.2 Merck and co. Main Business
7.7.3 Merck and co. TNF Alpha Inhibitor Products, Services and Solutions
7.7.4 Merck and co. TNF Alpha Inhibitor Revenue (US$ Million) & (2019-2024)
7.7.5 Merck and co. Recent Developments
7.8 Janssen Biotech
7.8.1 Janssen Biotech Profile
7.8.2 Janssen Biotech Main Business
7.8.3 Janssen Biotech TNF Alpha Inhibitor Products, Services and Solutions
7.8.4 Janssen Biotech TNF Alpha Inhibitor Revenue (US$ Million) & (2019-2024)
7.8.5 Janssen Biotech Recent Developments
7.9 Ablynx
7.9.1 Ablynx Profile
7.9.2 Ablynx Main Business
7.9.3 Ablynx TNF Alpha Inhibitor Products, Services and Solutions
7.9.4 Ablynx TNF Alpha Inhibitor Revenue (US$ Million) & (2019-2024)
7.9.5 Ablynx Recent Developments
7.10 Momenta
7.10.1 Momenta Profile
7.10.2 Momenta Main Business
7.10.3 Momenta TNF Alpha Inhibitor Products, Services and Solutions
7.10.4 Momenta TNF Alpha Inhibitor Revenue (US$ Million) & (2019-2024)
7.10.5 Momenta Recent Developments
8 Industry Chain Analysis
8.1 TNF Alpha Inhibitor Industrial Chain
8.2 TNF Alpha Inhibitor Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 TNF Alpha Inhibitor Sales Model
8.5.2 Sales Channel
8.5.3 TNF Alpha Inhibitor Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer